Objectives: The purpose of this study was to look into the benefit of a bariatric surgery in four artificial intelligence-assisted metabolic (AIM) subtypes of obesity with respect to the improvement of glucometabolism, as well as the remission of diabetes and hyperinsulinemia.

Methods: This multicenter retrospective study prospectively collected data from 5 hospitals in China from 2010 to 2021. A total of 1008 patients who underwent a bariatric surgery were enrolled (median age 31 years; median BMI 38.1kg/m2; 57.40% women) and grouped into four AIM subtypes of obesity. Data at baseline, 3- and 12-months post-surgery were collected for the longitudinal effect analysis.

Results: At baseline, the hypermetabolic obesity-hyperinsulinemia (HMO-I) group was characterized by severe insulin resistance and high incidence of hyperinsulinemia (87.8%) . After surgery, HMO-I with hyperinsulinemia had achieved remission, yet the prevalence of hypoglycemia was still high (42.9%) . Hypometabolic obesity (LMO) group showed decompensated insulin secretion and high incidence of diabetes (99.2%) at baseline. After surgery, 62.1% of LMO patients with diabetes achieved remission, lower than the other three groups. Still, the bariatric surgery significantly reduced their blood glucose (median HbA1c decreased by 27.2%) . For both metabolic healthy obesity (MHO) and hypermetabolic obesity-hyperuricemia (HMO-U) groups, who showed a relatively healthy glucometabolism at baseline, prevalence of glucometabolic comorbidities improved moderately after surgery.

Conclusion: This multicenter study found that the four AIM subtypes of obesity benefited differently from a bariatric surgery in terms of glucometabolism. Bariatric surgery significantly relieves hyperinsulinemia and hyperglycemia for HMO-I and LMO, respectively. As a result, patients of the two subtypes should be motivated for a bariatric surgery for the improvement of glucometabolism.

Disclosure

Y. Liu: None. C. Sheng: None. Z. Lin: None. S. Qu: n/a.

Funding

Clinical Research Plan of SHDC (No.SHDC2020CR1017B) , National Natural Science Foundation of China (82170861,81970677) , Shanghai Medicine and Health Development Foundation (DMRFP_I_07) , Shanghai Commission of Science and Technology (19DZ1910200)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.